The clinical studies of 30 cases perennial allergic rhinitis with special immunotherapy.
- Author:
Huizhen ZHANG
1
;
Qingquan HUA
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, People's Hospital of Wuhan Universtity, Wuhan, 430060, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Female;
Follow-Up Studies;
Humans;
Immunotherapy;
Interleukin-2;
blood;
Interleukin-4;
blood;
Interleukin-5;
blood;
Male;
Middle Aged;
Retrospective Studies;
Rhinitis, Allergic, Perennial;
therapy;
Young Adult
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2007;21(8):356-358
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy, safety and possible mechanism of specific immunotherapy in treating perennial allergic rhinitis.
METHOD:Thirty patients with perennial allergic rhinitis were treated by specific immunotherapy for three years. Its clinical symptoms and signs were retrospectively analyzed. Thirty patients were contacted once again in 2006 for a follow up study. Controlled group were 30 perennial allergic rhinitis patients who were treated with medication only (antihistamines and intranasal corticosteroids) when necessary. Healthy group were 10 healthy people without allergic rhinitis. the values of immunity index (IL-2, IL-4 and IL-5 level in venous blood) were observed.
RESULT:(1) The effect evaluation of SIT: The total effective rate was 90.00% in the treatment group post-treatment, 86.67% in controlled group. There was no significance between them (P > 0.05). The score of clinical symptoms and signs of pretreatment was 11.10 +/- 1.53, that of post-treatment was 3.88 +/- 2.71. There was significance between them by statistics evaluation (P < 0.01). (2) Blood serum IL-2, IL-4 and IL-5 determine: there was immunological dysfunction in controlled group patients, manifesting as low IL-2 level and high IL-4 and IL-5 level, which had significant difference compared with healthy group ( P < 0.01). The group treated by specific immunotherapy was better than controlled group, there was significant difference between them (P < 0.01). After treatment, there was no significant difference between the treated group and healthy group (P > 0.05). (3) Thirty patients with allergic rhinitis received 3530 times immunotherapy, their local and systemic side-effect were observed, recorded and analyzed during the treatment, the number of patients who got systemic side-effect was 4 cases, the percent of side-effect was 0.17% (6/3530); the number of patients who got local side-effect was 12 cases, the percent of local side-effect was 1.53% (54/3530). Both side-effects were slight.
CONCLUSION:Specific immunotherapy is a sort of effective method for treating perennial allergic rhinitis, so it is worth spreading.
